Лейоміосаркома матки – принципи діагностики та лікування
DOI:
https://doi.org/10.15574/101526Ключові слова:
лейоміосаркома матки, діагностика, лікуванняАнотація
У статті наведені дані про морфологічні особливості лейоміосаркоми матки; розглянуті діагностика, хірургічне лікування з урахуванням віку пацієнтки, ад’ювантна променева та хіміотерапія, подальше спостереження.
Ключові слова: лейоміосаркома матки, діагностика, лікування.
Посилання
Bohman YV, Urmancheeva AF. 1996. Uterine sarcoma. St. Petersburg, Hippocrates:128.
Ulrich EA. 2013. Features of treatment of uterine sarcomas. Practical Oncology 14;2:127-134.
Lazareva NI, Kuznetsov VV, Zakharova TI. 2005. Sarcoma. Clinical Oncology: Guide for Physicians. M, Publishing House. Medicine:178-219.
Kohanevich EV. 2009. Cervical and endometrial pathology. Guidelines for doctors. Nizhyn: Gydromaks:324-327.
FIGO Committee on Gynecologic Oncology. FIGO staging for uterine sarcomas. 2009. J. Gynaecol. Obstet. 104:179.
George Demetri D, Margaret von Mehren, Robin Jones L. 2015. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J. Clin.Onkol. 62.4734.
Hensley ML, Maki R, Venkatraman E et al. 2002. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20:2824–2831. http://dx.doi.org/10.1200/JCO.2002.11.050; PMid:12065559
Hensley ML, Wathen K, Maki RG et al. 2011. 3-year follow-up ot SARC005: adjuvant treatment ot high risk primary uterine leiomyosarcoma with gemcitabine/ docetaxel, followed by doxorubicin. Connective Tissue Oncology Society Annual Meeting. Chicago:78.
Mahdavi A, Monk BJ, Ragazzo J et al. 2009. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience. J. Gynaecol. Cancer. 19:1080-1084. http://dx.doi.org/10.1111/IGC.0b013e3181acae50; PMid:19820372
Maki RG. 2007. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist. Aug. 12(8):999-1006. http://dx.doi.org/10.1634/theoncologist.12-8-999
Morgan JA, Cesne ALe, Chawla SM et al. 2007. Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I) Journal of Clinical Oncology. ASCO Annual Meeting Proceedings (Post-Meeting Edition). 25;18S (June 20 Supplement):10060.
Omura GA, Blessing JA, Major F et al. 1985. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynaecologic Oncology Group Study. J. Clin. Oncol. 3:1240-1245.
Petru E, Jonat W, Fink D, Kochli O. 2009. Praxisbuch Gynakologische Onklogie. Springer. Heidelberg:60-65.
Reed NS, Mangioni C, Malmstrom H et al. 2008. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organization for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Europ. J. Cancer. 44:808-818. http://dx.doi.org/10.1016/j.ejca.2008.01.019; http://dx.doi.org/10.1016/j.ejca.2008.01.029
Sabelle Laure Ray-Coquard, Stefan Sleijfer, Saskia Litiиre et al. 2014. Pazopanib in uterine sarcoma (UtS): Review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS). .J. Clin. Oncol 32:5:s, (suppl; abstr 10579).
Sampath S, Schultheiss TE, Ryu JK et al. 2010. The role of adjuvant radiation in uterine sarcomas. J. Radiat. Oncol. Biol. Phys. 76:728-734. http://dx.doi.org/10.1016/j.ijrobp.2009.02.077; PMid:19700247
Sutton G, Blessing JA, Malfetano JH. 1996. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol 62:226–229. http://dx.doi.org/10.1006/gyno.1996.0220; PMid:8751554
